Clinical trial · Interventional
Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles
A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as bleomycin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of bleomycin is more effective when given together with etoposide and cisplatin in treating metastatic germ cell cancer of the testicles. PURPOSE: This randomized phase III trial is studying two different schedules of bleomycin to compare how well they work when given together with etoposide and cisplatin in treating patients with metastatic germ cell cancer of the testicles.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Drug/Agent Toxicity by Tissue/Organ | — | UNRESOLVED | — |
| Testicular Germ Cell Tumor | Testicular Germ Cell Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pulmonary toxicity
Secondary outcomes (3)
- measure
- Response to treatment
- measure
- Progression-free survival
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of metastatic germ cell cancer of the testes * Good-prognosis disease * Eligible for treatment with bleomycin, etoposide, and cisplatin PATIENT CHARACTERISTICS: * Creatinine clearance ≥ 60 mL/min * No other prior or concurrent malignancy except basal cell skin cancer * No other major systemic illness * No impaired respiratory function, including any of the following: * Shortness of breath on minimal exertion * Hypoxia at rest * Carbon monoxide transfer, total lung capacity, and FEV\_1 \> 60% of predicted PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy
References
Publications (0)
Data not yet available